Literature DB >> 8787869

Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes.

D P Healy1, M C Brodbeck, C E Clendening.   

Abstract

Twenty-six hospitalized patients participated in a randomized crossover study to evaluate the effect of enteral feedings on ciprofloxacin absorption when given orally or via gastrostomy or jejunostomy tubes. Patients in the oral group received an intact 500-mg ciprofloxacin tablet alone or ciprofloxacin plus three oral doses of Sustacal (240 ml given 8 h before, with, and 4 h after ciprofloxacin administration). Patients with gastrostomy or jejunostomy tubes received 500 mg of crushed ciprofloxacin in 60 ml water via the feeding tube. After a washout period, the patients received ciprofloxacin with a continuous enteral formula (Jevity) given at 60 to 90 ml/h beginning 6 h before drug administration and continuing for 10 h. Serial blood samples were analyzed for ciprofloxacin concentration by high-performance liquid chromatography. The maximum ciprofloxacin concentrations in serum for ciprofloxacin given and for ciprofloxacin plus enteral feeding for the oral, gastrostomy, and jejunostomy groups were (mean +/- standard deviation) 2.59 +/- 1.24 versus 1.43 +/- 0.61 micrograms/ml (P < 0.05), 3.68 +/- 1.36 versus 2.27 +/- 0.67 micrograms/ml (P < 0.05), and 3.78 +/- 1.87 versus 1.45 +/- 0.48 micrograms/ml (P < 0.05), respectively. Corresponding values for area under the concentration-time curve were 13.4 +/- 8.32 versus 9.44 +/- 4.74 micrograms/h/ml (P < 0.05) 15.9 +/- 6.62 versus 7.44 +/- 3.16 (micrograms/h/ml (P < 0.05), and 18.1 +/- 9.37 versus 5.82 +/- 2.63 micrograms.h/ml (P < 0.05). We conclude that enteral feedings given orally or via gastrostomy or jejunostomy tubes resulted in a 27 to 67% reduction in the mean bioavailability of ciprofloxacin in hospitalized patients. The decreased absorption may be clinically important, especially when the enteral feeding is coadministered with ciprofloxacin by the oral and jejunostomy tube routes. Reductions in maximum levels of ciprofloxacin in serum as a result of feedings given via a gastrostomy tube are similar to those following oral administration on an empty stomach, making a clinically important interaction by this route less likely.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8787869      PMCID: PMC163046     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Absorption of ciprofloxacin administered through a nasogastric or a nasoduodenal tube in volunteers and patients receiving enteral nutrition.

Authors:  J H Yuk; C H Nightingale; R Quintiliani; N S Yeston; R Orlando; E D Dobkin; J C Kambe; K R Sweeney; E A Buonpane
Journal:  Diagn Microbiol Infect Dis       Date:  1990 Mar-Apr       Impact factor: 2.803

Review 2.  Fluoroquinolone antimicrobial agents.

Authors:  D C Hooper; J S Wolfson
Journal:  N Engl J Med       Date:  1991-02-07       Impact factor: 91.245

3.  The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.

Authors:  J Sahai; D P Healy; J Stotka; R E Polk
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

4.  Cations in the didanosine tablet reduce ciprofloxacin bioavailability.

Authors:  J Sahai; K Gallicano; L Oliveras; S Khaliq; N Hawley-Foss; G Garber
Journal:  Clin Pharmacol Ther       Date:  1993-03       Impact factor: 6.875

5.  Logarithmic transformation in bioequivalence: application with two formulations of perphenazine.

Authors:  K K Midha; E D Ormsby; J W Hubbard; G McKay; E M Hawes; L Gavalas; I J McGilveray
Journal:  J Pharm Sci       Date:  1993-02       Impact factor: 3.534

Review 6.  Crossover studies: a modified analysis with more power.

Authors:  T J Cleophas
Journal:  Clin Pharmacol Ther       Date:  1993-05       Impact factor: 6.875

7.  Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin.

Authors:  B A Mueller; D G Brierton; S R Abel; L Bowman
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

8.  Effect of antacids in didanosine tablet on bioavailability of isoniazid.

Authors:  K Gallicano; J Sahai; G Zaror-Behrens; A Pakuts
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 9.  Fluoroquinolones: interaction profile during enteral absorption.

Authors:  K M Deppermann; H Lode
Journal:  Drugs       Date:  1993       Impact factor: 9.546

10.  Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis.

Authors:  G L Drusano; D E Johnson; M Rosen; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

View more
  13 in total

1.  Serum voriconazole levels following administration via percutaneous jejunostomy tube.

Authors:  Valérie Martinez; Jean-Luc Le Guillou; Christian Lamer; Melissande Le Jouan; Michel Tod; Françoise Dromer
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 2.  Addressing Concerns about Changing the Route of Antimicrobial Administration from Intravenous to Oral in Adult Inpatients.

Authors:  Lizanne Béïque; Rosemary Zvonar
Journal:  Can J Hosp Pharm       Date:  2015 Jul-Aug

Review 3.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Clinical Equivalency of Ciprofloxacin 750 mg Enterally and 400 mg Intravenously for Patients Receiving Enteral Feeding: Systematic Review.

Authors:  Donna Chui; Lily Cheng; Aaron M Tejani
Journal:  Can J Hosp Pharm       Date:  2009-03

5.  Bioavailability of ciprofloxacin after multiple enteral and intravenous doses in ICU patients with severe gram-negative intra-abdominal infections.

Authors:  S de Marie; M F VandenBergh; S L Buijk; H A Bruining; A van Vliet; J A Kluytmans; J W Mouton
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

Review 6.  Pharmacokinetics of drugs used in critically ill adults.

Authors:  B M Power; A M Forbes; P V van Heerden; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

7.  Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings.

Authors:  Paul Beringer; Megan Nguyen; Nils Hoem; Stan Louie; Mark Gill; Michael Gurevitch; Annie Wong-Beringer
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

8.  In vivo interaction between ciprofloxacin hydrochloride and the pulp of unripe plantain (Musa paradisiaca).

Authors:  Nwafor Sv; Esimone Co; Amadi Ca; Nworu Cs
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Oct-Dec       Impact factor: 2.441

9.  Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia.

Authors:  Pranita D Tamma; Anna T Conley; Sara E Cosgrove; Anthony D Harris; Ebbing Lautenbach; Joe Amoah; Edina Avdic; Pam Tolomeo; Jacqueleen Wise; Sonia Subudhi; Jennifer H Han
Journal:  JAMA Intern Med       Date:  2019-03-01       Impact factor: 21.873

Review 10.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.